| Literature DB >> 24410810 |
Kenny Kung, Kai Ming Chow, Eric Ming-Tung Hui, Maria Leung, Shuk Yun Leung, Cheuk Chun Szeto, Augustine Lam, Philip Kam-Tao Li1.
Abstract
BACKGROUND: A territory-wide diabetes management program (Risk Assessment Management Program - RAMP) was recently established, providing comprehensive management for all diabetics, helping to delineate current level of control and complications prevalence among primary care diabetic patients in Hong Kong.Entities:
Mesh:
Year: 2014 PMID: 24410810 PMCID: PMC3913315 DOI: 10.1186/1471-2296-15-8
Source DB: PubMed Journal: BMC Fam Pract ISSN: 1471-2296 Impact factor: 2.497
Sociodemographics of study population
| Female | 51.2% | |
| Male | 48.8% | |
| 20-29 | 0.1% | |
| 30-39 | 1.1% | |
| 40-49 | 9.2% | |
| 50-59 | 32.4% | |
| 60-69 | 29.4% | |
| 70-79 | 20.7% | |
| 80-89 | 6.8% | |
| >89 | 0.2% | |
| Never-smoked | 71.6% | |
| Ever-smoked | 28.4% | |
| Non-drinker | 76.1% | |
| Ever-drinker | 23.9% | |
| None | 18.0% | |
| Primary | 40.2% | |
| Secondary | 37.0% | |
| Tertiary or above | 4.8% | |
| Housewife | 28.8% | |
| Professional | 1.9% | |
| Non-manual | 10.6% | |
| Manual skilled | 10.4% | |
| Manual non-skilled | 8.8% | |
| Unemployed | 4.3% | |
| Retired | 35.2% | |
| <18.5 | 1.2% | |
| 18.5-22.9 | 22.3% | |
| 23-24.9 | 21.9% | |
| 25-27.4 | 26.3% | |
| 27.4-30 | 15.8% | |
| >30 | 12.4% | |
| Low (<0.8 female; <0.96 male) | 25.8% | |
| Moderate (0.81-0.85 female; 0.96-1.0 male) | 28.0% | |
| High (>0.85 female; >1.0 male) | 46.2% | |
| None | 62.2% | |
| Urine testing only | 1.1% | |
| Finger prick testing | 36.3% | |
| 7.3 years | ||
| Hypertension | 57.6% | |
| Coronary heart disease | 3.8% | |
| Stroke | 4.5% | |
Lipid profile and eGFR among study population
| Systolic | 138 mmHg | (18.3) |
| Diastolic | 76 mmHg | (10.5) |
| TC | 5.0 mmol/L | (0.9) |
| LDL | 3.1 mmol/L | (0.8) |
| HDL | 1.2 mmol/L | (0.3) |
| TG | 1.6 mmol/L | (1.1) |
| Total cholesterol* | ||
| <5.2 | 60.9% | |
| 5.2-6.2 | 28.8% | |
| >6.2 | 9.9% | |
| LDL* | | |
| <2.6 | 30.4% | |
| 2.6-3.3 | 35.9% | |
| 3.4-4.1 | 23.2% | |
| 4.1-4.9 | 7.4% | |
| >4.9 | 2.1% | |
| HDL* | ||
| <1.0 | 16.5% | |
| 1.0-1.5 | 53.6% | |
| >1.5 | 29.5% | |
| TG* | ||
| <1.7 | 68.1% | |
| 1.7-2.2 | 16.4% | |
| 2.3-5.6 | 14.1% | |
| >5.6 | 1.0% | |
| 84.8 | (23.2) | |
| Stage 1 | 38.5% | |
| Stage 2 | 48.8% | |
| Stage 3 | 11.7% | |
| Stage 4 | 0.3% | |
| Stage 5 | 0.1% | |
| 10.2 mg/mmol | (42.7) | |
| Proportion normal | 67.9% | |
TC: total cholesterol; LDL: low density lipoprotein; HDL: high density lipoprotein; TG: triglyceride; ACR: albumin to creatinine ratio.
*Percentages may not add up to 100% because of missing data.
Figure 1Distribution of HbA1c values among study population.
Drug use among study population
| 15.0% | |
| | |
| Metformin | 64.5% |
| Sulphonylurea | 54.5% |
| Glitazone | 0.5% |
| Gliptin | 0.1% |
| Insulin | 1.6% |
| | |
| None | 35.4% |
| ACEI or ARB | 38.2% |
| β-blocker | 26.6% |
| CCB | 41.8% |
| Diuretic | 13.2% |
| | |
| Statin | 22.2% |
| Fibrate | 3.7% |
| 9.4% |
ACEI: angiotensin converting enzyme inhibitor.
ARB: angiotensin receptor blocker.
CCB: calcium channel blocker.
*Percentages do not add up to 100% because some patients may be taking more than one therapy.
Prevalence of diabetic complications
| | |
| Mild non-proliferative | 12.1% |
| Moderate to severe non-proliferative | 0.5% |
| Proliferative | 0.3% |
| | |
| Incipient | 30.9% |
| Overt | 7.9% |
| 2.4% | |
| Reported numbness | 5.4% |
| Presence of foot ulcer | 0.5% |
| Absent foot pulses | 0.2% |
| Foot deformity | 4.3% |
| Presence of callosity | 30.3% |
| Presence of suspected skin infection | 2.2% |
| Nail abnormalities | 7.3% |
| 15.0% |
Figure 2Prevalence of complications among study population.